FDA approved international key Phase III clinical trial scheme on XNW4107 developed by Evopoint for indications of HAP/VAP in April 2022

XNW4107 is a β-lactamase inhibitor with independent intellectual property rights owned by Evopoint. It has excellent antibacterial activities when combining with Imipenem and Cilastatin (β-lactam antibiotics) against carbapenem-resistant bacterial infections that has an increased incidence in recent years, such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Enterobacteriaceae (CRE), etc.